Clinical Trial Update: Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ARN-509 (apalutamide) with or without abiraterone acetate, a GnRH analog, and prednisone in high-risk prostate cancer patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Lupron (leuprolide)
• PREDNISONE (Prednisone)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING